scott kopetz, md, explains how braf mutations figure into treatment algorithms for crc
Published 4 years ago • 72 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
0:30
scott kopetz, md, phd, facp, explains how nivolumab is being incorporated into mcrc treatment
-
0:38
scott kopetz, md, phd, facp, discusses the incidence of braf mutation in crc patients
-
1:44
dr. kopetz discusses the treatment of braf-mutant crc
-
1:35
scott kopetz, md, shares updates from the beacon trial in braf-mutant colorectal cancer
-
1:00
dr. kopetz discusses triplet therapy for braf-mutant crc
-
1:11
dr. kopetz on the rationale for the beacon crc study in braf v600e-mutant mcrc
-
1:09
dr. kopetz on updated data from beacon crc study in braf v600e–mutant crc
-
1:59
scott kopetz, md, phd, facp, on the implications of the beacon phase 3 study in braf-mutant mcrc
-
8:02
appendix tumours/cancers for cytoreductive surgery (crs) hipec
-
2:03
breast biopsy animation
-
28:10
biomarkers of cancer
-
1:18
how braf v600e-mutated crc is treated differently than other cancers
-
0:54
dr. kopetz on safety data from beacon crc trial in braf v600e-mutant mcrc
-
1:38
dr. kopetz on the correlation between tumor sidedness and biomarkers in crc
-
1:14
dr. kopetz on the importance of molecular testing in crc
-
29:45
keynote lecture 4: the braf pathway in crc?
-
1:34
dr. kopetz on the biology of right- versus left-sided crc
-
22:10
novel agents and targets in colorectal cancer
-
1:54
dr. kopetz on the rationale and primary endpoints of the beacon crc study in mcrc
-
2:24
real-world management of patients with braf-v600e mcrc
-
1:39
dr. kopetz on the significance of tumor sidedness in crc
-
0:57
scott kopetz, md, phd, facp, on the potential of binimetinib immunotherapy in mcrc patients